Heat Biologics Inc. buy melinda
Startpreis
24.11.18
/
50%
8,97 €
Kursziel
22.01.19
12,63 €
Rendite (%)
-4,23 %
Endpreis
22.01.19
8,59 €
Zusammenfassung
Diese Einschätzung wurde am 22.01.19 mit einem Endkurs von 8,59 € beendet. Einen leichten Verlust von -4,23 % verzeichnete die BUY Einschätzung von melinda. melinda hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
Name | 1W | 1M | 1J | 3J |
---|---|---|---|---|
Heat Biologics Inc. | -2,37 % | -2,37 % | -73,60 % | -96,81 % |
iShares Core DAX® | 4,09 % | 3,54 % | 17,40 % | 20,33 % |
iShares Nasdaq 100 | 1,42 % | 0,51 % | 39,21 % | 55,37 % |
iShares Nikkei 225® | -1,57 % | -4,63 % | 15,73 % | 2,15 % |
iShares S&P 500 | 1,82 % | 0,96 % | 30,40 % | 45,95 % |
Kommentare von melinda zu dieser Einschätzung
In der Diskussion Heat Biologics Inc. diskutieren
SecteurRecherche biotechnologique et médicale
Operates as a clinical stage biopharmaceutical company with interest in the development of novel allogeneic drugs
Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer.
The firm's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness.
Its TCAP product candidates from the firm's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers.
The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Durham, NC.
Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer.
The firm's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness.
Its TCAP product candidates from the firm's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers.
The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Durham, NC.
Nombre d'employés : 19 personnes.
(Vom Mitglied beendet)
Beendete Einschätzungen von melinda zu Heat Biologics Inc.
Heat Biologics Inc.
Startkurs
Kursziel
Rendite (%)
66,20 €
13.03.17
13.03.17
75,77 €
13.09.17
13.09.17
-44,67 %
13.09.17
13.09.17